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Cardiovascular disease (CVD) is the leading cause of death and disease 
globally, representing 31% of all global deaths.1 The traditional 
management of CVD has largely depended on the face-to-face clinic 
visits once the clinical events occurred. CVD contributes to and 
exacerbates the economic burden on households.2 However, most of 
these complications could be avoided with early diagnosis and effective 
prevention or interventions.
With increasing advances in mobile health (mHealth), smart technology 
is emerging as a novel tool to improve disease prevention and 
management. Some exploring studies demonstrated that the alerts or 
text message intervention using mHealth technology might help 
patients in implementing changes in lifestyle behaviours or drug 
adherence.3 However, there are many gaps in knowledge when 
considering mHealth for CVD management.3,4 For example, how could 
wearable sensors (mobile devices) be used to improve healthcare, 
beside using the communication function (mobile phone) of mHealth 
technologies? Would mHealth-supported approaches impact on 
important CVD outcomes, including hospitalisations?
The Mobile Health technology for improved screening and optimising 
integrated care in Atrial Fibrillation (the mAFA-II programme) provides 
some new evidence for this.5 The mAFA II programme included 
the pre-mAFA phase to investigate the incidence of AF with 
photoplethysmography (PPG)-based screening strategy among the 
general population, using Huawei smart devices (hence, called 
the Huawei Heart Study); and the AFA II trial, which was used to validate 
a holistic or integrated care approach, the Atrial Fibrillation Better Care 
pathway (ABC) pathway, supported by mHealth technology for the 
management of AF. 
The ABC (AF Better Care) Pathway simplifies the management of AF, as 
follows (‘easy as ABC…’): 
• ‘A’ Anticoagulation to avoid stroke – anticoagulation with non-
vitamin K antagonist oral anticoagulant or well-managed warfarin.
• ‘B’ Better symptom management with patient-centred symptom-
directed shared decisions for rate or rhythm control. 
• ‘C’ Cardiovascular risk and comorbidity management (blood 
pressure, sleep apnoea etc) plus lifestyle changes (weight reduction, 
regular exercise, reducing alcohol/stimulants, psychological 
morbidity, smoking cessation etc).6,7
AF Screening Using Smart Technology
The predictive ability of AF screening using smart technology would be 
influenced by several factors: monitoring technology PPG, single-lead 
ECG, the frequency of monitoring (single-point or twice a day etc), 
monitoring duration (7  days, 14  days etc), the type of smart devices 
(smart bands, ePatch or hand-held devices) and the patient population 
with different risk profiles. For a single-lead ECG-based approach to 
detect AF detection, there could also be the instability of signal quality 
of the wristband due to motion artefacts.8,9 A lower AF burden requires 
a longer monitoring time. 
Two large population-based smartwear studies have been published. In 
the Apple Heart Study: Assessment of Wristwatch-Based 
Photoplethysmography to Identify Cardiac Arrhythmias; (NCT03335800), 
419,297 participants using Apple Watch were recruited over 8 months, 
and 0.52% received notifications of irregular pulse: AF was present in 
34% and 84% of notifications were concordant with AF.10 In the Huawei 
Heart Study, a PPG algorithm and smart devices used were validated 
with a total of 29,485 PPG signals before starting the mAFA II 
programme.11,12 Both the pilot study and the Huawei Heart Study 
demonstrated a consistent predictive ability for  AF of >91% with 
continuous monitoring mode in a real-world setting.12,13 In the study, 
about one-third of AF episodes were detected over 14 days. However, 
the comfort factor of monitoring should be balanced with the 
monitoring time and type of smart device(s) used. Nearly one-third of 
subjects refused to use the ECG skin adhesive patch for 14-day 
monitoring, and some individuals reported skin irritation, resulting in 
early discontinuation of structured management in one study.14 Even 
with a PPG technology-based wristband, more frequent monitoring 
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might contribute to much higher predictive ability. For example, the 
positive predictive value of detecting AF was 91.6% in the Huawei Heart 
Study with periodic measurements every 10 minutes on baseline, 
compared with 71.3% in the Apple Heart Study with periodic 
measurements every 2 hours.13,15 
In the Huawei Heart Study, there were 0.23% of subjects with suspected 
AF using smart devices in the general population, with the highest 
proportion of AF episodes among the elderly, i.e. those aged over 65 
years, with a prevalence of 2.78%.13 This leads to more questions, for 
example, whether AF screening should be a population-wide approach, 
with associated logistic and cost issues, or should be targeted screening 
of patients at high risk of developing AF or those where greater efforts 
should be directed towards AF detection (for example, post stroke). Not 
only did the Huawei Heart Study demonstrate that AF screening with 
wearable devices was feasible, but also that the detected patients 
could be entered into an integrated care AF pathway to facilitate AF 
management. Thus, 95% of those with identified AF from the general 
population entered into ABC pathway management using a mobile 
Atrial Fibrillation Application (mAFA), and consequently 80% of high-risk 
patients were anticoagulated.13
 
mHealth-supported AF Integrated 
Care and CVD Outcomes
Subjects with identified AF were considered for entry into the mAFA-II 
clinical trial. The mAFA-II programme included an investigation of 
mHealth-supported AF management, and its impact on the composite 
of stroke/thromboembolism, all-cause death and rehospitalisation.5 
Using a prospective cluster randomised trial design, the mAFA-II trial 
randomised AF patients to a mAFA intervention arm and usual care 
arm. In the mAFA intervention group, doctors used the mAFA platform 
to manage AF patients, providing clinical decision support tools, 
educational materials and patient involvement strategies with self-care 
protocols and structured follow-up to support implementation of the 
ABC pathway for AF patients.7,16 The trial showed that an integrated 
care approach with mAFA intervention (easy as ABC… ), supported by 
mobile health technology, significantly reduced the risks of 
rehospitalisation and the composite of stroke/thromboembolism, all-
cause death and rehospitalisation care (1.9% versus usual care, 6.0%; 
HR 0.39; 95% CI [0.22–0.67]; p<0.001).17 Rates of rehospitalisation were 
also lower with the mAFA intervention (1.2% versus 4.5%; HR 0.32; 95% 
CI [0.17–0.60]; p<0.001). 
The mAFA programme is the first integrated programme that links AF 
screening with eligible patients subsequently entered into a structured 
care pathway with mHealth technologies, highlighting the potential 
application of mHealth bridging primary care to secondary care 
management, as well as patient empowerment.
Integrated Care for CVD: The New Frontier
Other integrated care approaches for AF management have included 
nurse-led integrated care, a post-discharge integrated care of home 
visits and 7- to 14-day Holter monitoring and AF care focused on 
optimising anticoagulation with trained nurses in primary care.18–20 
There are growing challenges and opportunities on how best to apply 
mHealth technology into CVD prevention and management, for 
example how these novel technologies could be used to improve the 
quality of care without driving up costs and how mHealth technology 
could be applied into special populations, for example, in the 
management of the elderly, those with multimorbidity etc. Indeed, we 
need to know the advantages of smart technology in streamlining 
clinical management pathways, not only through better real-time 
communications but also with data-driven intelligent management. 
We have no doubt that current smart devices will increasingly improve 
their specifications over time, providing better-quality signals and 
diagnostics, long battery life and improved capability for clinical 
settings. These would need to be balanced against management of 
comorbidities, costs and clinical setting. Using PPG-based heart rate 
and physical activity levels, artificial intelligence and machine learning 
can potentially be explored to diagnose AF without recoring and 
documenting an ECG.21 Although there are some limitations (positive 
predictive value for AF episodes of 39.9%, detected AF ≥1 hour etc) in 
the current stage, this study highlights the potential use of artificial 
intelligence and smart devices in predicting the risk for subsequent AF.
Nevertheless, decision-making on holistic clinical care cannot be based 
on only what a smart device says. Physician-patient interactions remain 
central to optimal clinical management, hence our challenge is to 
streamline the patient pathway that bridges primary and secondary care, 
cardiologists and non-cardiologists, and – of course – the patient. In the 
case of AF, patients would present to general practitioners (often 
asymptomatically in the setting of a health check), hospital practitioners 
who may be non-cardiologists (emergency room, internal medicine, 
stroke wards, surgeons) and cardiologists (who may or may not be 
arrhythmia specialists). Ultimately, the patient may get different messages 
on their management from all these healthcare professionals they 
encounter, given the perception that AF management is difficult and 
complex. Using the ABC pathway above, AF management can be as ‘easy 
as ABC…’ and, even more so, supplemented by mHealth technology. 
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